A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease; Rectal fistula
- Focus Therapeutic Use
- Acronyms Divergence2
- Sponsors Gilead Sciences
- 23 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Apr 2020.
- 23 Mar 2018 Planned primary completion date changed from 1 May 2019 to 1 Apr 2020.
- 08 May 2017 New source identified and integrated: European Clinical Trials Database (EudraCT2016-003153-15).